Economic Observation Network reporter Huang Yifan On December 19, Fosun Pharma (600196.SH) announced that its subsidiary Fosun Industrial (Hong Kong) Co., Ltd. has received the “Drug/Product Registration Certificate”.
The announcement shows that the new mRNA corona vaccine BNT162b2 (hereinafter referred to as “Fubitai BNT162b2”) and original strain/mutant strain Omicron BA.4-5 bivalent vaccine (hereinafter referred to as “Fubitai Bivalent Vaccine”) introduced by the company are all been approved Officially registered as a drug/product (biological product) in the Hong Kong Special Administrative Region of China.
Among them, Fubitai BNT162b2 has been registered for primary immunization of persons 12 years of age and older, and Fubitai bivalent vaccine has been registered for booster vaccination of persons 12 years of age and older.
Previously, Fubita BNT162b2, related children’s dosage forms, children’s dosage forms, and Fubita bivalent vaccine were approved for Emergency Use Authorization (EUA) by Hong Kong, China, for the vaccination programs of the local government.
A person from Fosun Pharma said that after the registration of the above vaccines, those who are willing to get vaccinated can receive the vaccines at medical institutions or clinics in Hong Kong, China with the prescription of a local doctor and the scope of use it will no longer be limited to the local government vaccination plan.
It is understood that the new mRNA corona vaccine Fubitai (BNT162b2) has been used for emergency use in Hong Kong and Macao since March 2021 and has been included in the government’s vaccination plan, that is, only local residents in Hong Kong can be get vaccinated. After being approved as an officially registered drug this time, it means that mainland residents can travel to Hong Kong to inoculate Fubitai at their own expense in the future.
According to another announcement, Fubitai BNT162b2 has also been approved as a routinely imported vaccine in Macau and can be vaccinated at medical institutions or clinics in Macau, China with a prescription from a local doctor.
According to the booking website, at present, Macao can only make an appointment to receive the original Fubitai vaccine. According to Fosun Pharma’s announcement, the original Fubitai BNT162b2 and Fubitai bivalent vaccine have been approved in Hong Kong Special Administrative Region Kong. Vaccines against the Omicron variants are all approved.
Copyright Notice:The above content is the original work of “Economic Observer” and the copyright belongs to “Economic Observer”. Without the permission of the “Economic Observer”, reprinting or mirroring is strictly prohibited, otherwise the legal liability of the relevant actors will be investigated according to the law. For copyright cooperation, please call:[010-60910566-1260].
